Research programme: anticancer antibodies - BioInvent International/University of Southhampton
Latest Information Update: 03 Jul 2015
At a glance
- Originator BioInvent International; University of Southampton
- Class Antibodies
- Mechanism of Action Regulatory T-lymphocyte modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Jun 2015 Early research in Cancer in Sweden and United Kingdom (unspecified route)